Mutant KRAS at the Heart of Tumor Immune Evasion

Febe van Maldegem; Julian Downward

doi:10.1016/j.immuni.2019.12.013

Mutant KRAS at the Heart of Tumor Immune Evasion

Immunity. 2020 Jan 14;52(1):14-16. doi: 10.1016/j.immuni.2019.12.013.

Authors

Febe van Maldegem¹, Julian Downward²

Affiliations

¹ Oncogene Biology, Francis Crick Institute, London NW1 1AT, UK. Electronic address: febe.vanmaldegem@crick.ac.uk.
² Oncogene Biology, Francis Crick Institute, London NW1 1AT, UK; Lung Cancer Group, Institute of Cancer Research, London SW3 6JB, UK. Electronic address: julian.downward@crick.ac.uk.

PMID: 31951548
DOI: 10.1016/j.immuni.2019.12.013

Abstract

In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al. (2019) describe how the novel KRAS-G12C inhibitor AMG 510 can potentiate immune rejection in combination with immune checkpoint blockade.

Publication types

Comment

MeSH terms

Antineoplastic Agents*
Humans
Immunotherapy
Neoplasms*
Proto-Oncogene Proteins p21(ras)
Tumor Escape

Substances

Antineoplastic Agents
KRAS protein, human
Proto-Oncogene Proteins p21(ras)